Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
In new antiarrhythmic drug development, key comparisons include those with placebo, standard (class I) agents and other beta blockers. This review will cover the first 2 comparisons. The effectiveness of 2 doses of sotalol for complex ventricular arrhythmias has been compared with placebo in a 6-week, multicenter study (parallel, double-blind design) in 102 patients. The frequency of ventricular premature complexes (VPCs) was reduced only 10% with placebo, 75% with low-dose sotalol (160 mg administered twice daily) and 88% with high-dose sotalol (320 mg administered twice daily) (both p less than 0.05 vs placebo). The defined efficacy criterion (greater than or equal to 75% VPC suppression) was achieved by 6% of patients taking placebo, 34% of patients taking low- and 71% of patients taking high-dose sotalol. Sotalol was generally well tolerated, especially with the lower dose. Heart rate decreased, and PR and QTc intervals increased modestly. An open, randomized, crossover study compared sotalol with procainamide in 33 patients. A reduction in VPCs of greater than or equal to 75% was achieved in 22 patients (67%) with sotalol and in 13 patients (39%) with procainamide. Quinidine and sotalol have also been compared in a multicenter study in patients with chronic, complex VPCs, with results to be presented in the near future. Thus, sotalol's antiarrhythmic efficacy is well demonstrated by comparisons with placebo, and its effectiveness and tolerance are likely to compare favorably with standard class I drugs, suggesting its potential as a first-line antiarrhythmic agent.
Department of Medicine, University of Utah, Salt Lake City.
J L
JL
Anderson
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004311:Double-Blind Method; D006352:Heart Ventricles; D006801:Humans; D015337:Multicenter Studies as Topic; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013015:Sotalol / Q000009:adverse effects / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D011802:Quinidine; D011342:Procainamide